Drug Profile
BB MPI 03
Alternative Names: BB-MPI-03; iLRP multi-peptide cancer vaccine - Benovus Bio; Immature laminin receptor protein multi-peptide cancer vaccine - Benovus Bio; OFA multi-peptide cancer vaccine - Benovus Bio; OFA multi-peptide immunotherapy - Benovus-Bio; Oncofetal antigen multi-peptide cancer vaccine - Benovus Bio; Oncofoetal antigen multi-peptide cancer vaccine - Benovus BioLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Benovus Bio
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (Intradermal, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Multiple-myeloma in USA (Intradermal, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (Intradermal, Injection)